RxDoctor Payments Data

Jonathan Jakubowski, MD

Nephrology · Billings, MTNPI 1205322286

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.7% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 49.5% of the total. Reporting peaked in 2023 at $223 and has fallen 91.6% since, to $19 in 2025.

$300in general payments, 2019–2025

Across 6 payments — averaging $50.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$149
  • AstraZeneca$75
  • Abiomed$24
  • Bayer$19
  • Boehringer Ingelheim$19
  • Baxter Healthcare$15

What the payments were for

  • Food & beverage$28194%
  • Education$196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few nephrology providers in Montanato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$288,334
Medicare patients
643
Services billed
2,242

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$14,826
JardianceEmpagliflozin18$14,403
Potassium Citrate ErPotassium Citrate35$3,890
Bumetanide37$1,646
Mycophenolic AcidMycophenolate Sodium11$1,181
Midodrine Hcl21$1,155
Calcitriol42$989
Potassium Chloride35$852
Torsemide51$798
Hydralazine Hcl79$778
Spironolactone62$715
Losartan Potassium76$691
Chlorthalidone52$669
Doxazosin Mesylate19$534
Amlodipine Besylate103$525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$75$14,82619 claims
Boehringer IngelheimJardiance$19$14,40318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few nephrology providers in Montanaon file to place this against a meaningful peer group, so we don't.

Other nephrology in Billings

See the full list for Montana

Where these figures come from

Is this you, or does something look wrong? →